498 - Real-world use and effectiveness of upadacitinib in ad…
Emerging
2
Citations0
Refs2024
Year
Search Works
Work Details
- DOI 10.1093/bjd/ljad498.009
- OpenAlex ID W4391609609
- Type Article
- Language EN
- Published 01 Feb 2024
- Volume 190 (Supplement_2)
- Pages ii7–ii8
- Source British Journal of Dermatology
- Publisher Oxford University Press
- FWCI 0.82
- Countries 3
- Institutions 11
- Added 08 Feb 2024
- Updated 29 Sep 2026
External Links
MENU
0
498 - Real-world use and effectiveness of upadacitinib in adults and adolescents with atopic dermatitis: preliminary analysis of the real-world multicountry AD-VISE study
Article 2024 EN
Abstract Introduction & Objectives Upadacitinib (UPA) 15 and 30 mg once daily is approved for moderate to severe atopic dermatitis (AD) in several jurisdictions, including the European Union, Japan, Canada, and the United States, with indication/posology differences. Clinical studies have documented the safety and efficacy of UPA; however, real-world data on UPA are limited. The AD-VISE study obje…
2
Citations
0
References
10
Authors
0.82
FWCI
Citations by Year
Last 2 yearsTopics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
10 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Hermenio Lima | McMaster University (CA) | |
| 2 | J Rodríguez | Hospital Universitario Virgen … (ES) | |
| 3 | Jennifer R. Beecker | University of Ottawa (CA) Ottawa Hospital Research Insti… (CA) | |
| 4 | Charles W Lynde | University of Toronto (CA) Lynde Centre for Dermatology (CA) | |
| 5 | Cristina Sancho | AbbVie (Spain) (ES) | |
| 6 | Michael Lane | AbbVie (United States) (US) | — |
| 7 | Hongwei Wang | AbbVie (United States) (US) | |
| 8 | Brian Calimlim | AbbVie (United States) (US) | |
| 9 | Yolanda Armendáriz | AbbVie (United States) (US) | — |
| 10 | Melinda Gooderham | Queen's University (CA) SKiN Health (CA) +1 |
Related Works
10Data: OpenAlex